DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Valacyclovir (Cont.):
mechanism of action of, 1594
for ophthalmic use, 1782, 1783t
pharmacokinetics of, 1895t
resistance to, 1594
SLC transporters and, 102t
therapeutic uses of, 1597–1598
untoward effects of, 1597
VALCYTE (valganciclovir), 1783t
Valdecoxib, 964–965
COX isoform selectivity, 962f
pharmacology of, 962f
plasma pharmacokinetics of, 962f
Valganciclovir, 1603–1604
for ophthalmic use, 1783t
pharmacokinetics of, 1895t
Validation, of drug targets, 6
VALIUM (diazepam), 466t
Valnoctamide, 130
Valproic acid, 596–598
manifestation of overdose
symptoms, 75t
microsomal epoxide hydrolase and,
130
pharmacokinetics of, 1896t
Valproic acid poisoning, 75
Valsartan
as antihypertensive agent, 774t,
785–786
clinical pharmacology of, 738
pharmacokinetics of, 1896t
structure of, 737f
VALTREX (valacyclovir), 1596t, 1783t,
1818
VALTURNA, 786
Valvular heart disease
left-sided, angina pectoris with,
recommended treatment for,
769t
prophylaxis in surgery, 1488
VAMP2. See Vesicle-associated
membrane protein 2
(VAMP2)
Vancomycin, 1539–1542
histamine and, 914
pharmacokinetics of, 1897t
Vanillylmandelic acid (VMA),
200–201
VANIQA (eflornithine), 1841
VANTAS (histrelin), 1764t, 1765
VANTIN (cefpodoxime proxetil),
1494t
VAPRISOL (conivaptan), 714
Vardenafil, 758–759
effects on optic nerve, 1792
pharmacokinetics of, 1897t
Varenicline
pharmacokinetics of, 1897t
for smoking cessation, 272
Variability, pharmacodynamic, 48–50
Variants, genetic, types of, 147–149
Variation, genetic, frequency of, 145
Varicella-zoster virus (VZV), 1818
drugs for, 1599
Vascular disease, inflammatory,
eicosanoids and, 947
Vascular endothelial growth factor
(VEGF), 1738
Vascular endothelial growth factor
(VEGF) receptors,
1738–1739
Vascular tone, eicosanoids and,
946–947
Vasculitis, IVIG for, 1827
Vas deferens, alpha adrenergic
receptors in, 203t
Vasectomy, one-year failure rate, 1834t
Vasoactive intestinal peptide (VIP), and
vasopressin secretion, 704
Vasoactive intestinal polypeptide
(VIP), 172, 175, 182
for asthma, 1046
Vasoconstriction, ocular, autonomic
agents for, 1786t
Vasodilation
acetylcholine and, 220–221
histamine and, 916–917
Vasodilators
as antihypertensive agents, 774t,
786–783
arterial, as antihypertensive agents,
774t
arterial and venous, as
antihypertensive agents, 774t
arteriolar, hemodynamic effects of,
with long-term
administration, 774t
for heart failure, 793–797
Vasopressin
antidiuretic response to,
pharmacological
modification of, 707–708
arginine, 1213–1214
and blood coagulation, 708
cardiovascular effects of, 708
CNS effects of, 708
and diabetes insipidus, 710–711
evolutionary history of, 701
nonrenal actions of, 708
physiology, 701–704
plasma levels, plasma osmolality
and, 703, 703f
Vasopressin (Cont.):
and renal conservation of water, 707,
707f
secretion, regulation of, 703–704
hepatic portal osmoreceptors and,
703
hormones and neurotransmitters
in, 704
hyperosmolality and, 703
hypotension and, 703–704
hypovolemia and, 703
by pharmacological agents, 704
and SIADH, 711–712
synthesis of, 702, 702f
outside CNS, 702
transport and storage of, 702
in water-retaining states, 712
Vasopressin analogs, advances in
(future directions for), 717
Vasopressin peptide(s), synthetic, 709t
Vasopressin receptor agonists
adverse effects and side effects of,
713–714
contraindications to, 713
drug interactions with, 713
pharmacokinetics of, 713
therapeutic uses of, 712–714
toxicity of, 713
Vasopressin receptor antagonists,
708–710, 715t–716t
chemistry, 710
for heart failure, 799–800
nonpeptide, 715t–716t
peptide, 715t
therapeutic uses of, 714
V 1
-selective, 715t
V 2
-selective, 715t–716t
Vasopressin receptor-effector coupling,
705–707, 705f, 706f
Vasopressin receptors, 704–707
V 1
, therapeutic therapeutic uses of of
vasopressin agonists
mediated by, 712–714
V 2
, therapeutic therapeutic uses of of
vasopressin agonists
mediated by, 712–714
V 1
receptor-effector coupling, 705,
705f
V 2
receptor-effector coupling,
705–707, 706f
VASOTEC (enalapril maleate), 733, 797
VASOTEC INJECTION (enalaprilat), 733
Vasotocin, 709t
VECTIBIX (panitumumab), 1737
Vectorial transport, 96–97, 96f,
108–109
2081
INDEX